MaxCyte (MXCT) has released an update.
MaxCyte Inc., a cell-engineering company listed on NASDAQ and LSE, announced the successful passage of all resolutions at its recent Annual General Meeting. The company specializes in platform technologies that enhance the development of cell-based therapies, backed by over 20 years of expertise and a strong intellectual property portfolio. MaxCyte’s ExPERT platform is poised to support the burgeoning cell therapy market throughout the entire development and commercialization process.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
